Vioxx: lessons for Health Canada and the FDA
- FDA requests further data on Merck's Arcoxia application. // PharmaWatch: CNS;December2004, Vol. 3 Issue 12, p16
Reports that the U.S. Food and Drug Administration has informed Merck & Co. that it will require further safety and efficacy information before granting approval of Merck's new drug application for the COX-2 inhibitor, Arcoxia. Company's revision of its new drug application to the agency to...
- Vioxx. // Formulary;May2004, Vol. 39 Issue 5, p235
Provides information on Merck & Co. Inc.'s cyclooxygenase-2 inhibitor Vioxx, or rofecoxib, which has been approved by the U.S. Food and Drug Administration for the treatment of migraine. Mechanism of action; Drug efficacy; Safety; Dosing.
- Blow for Merck as FDA rejects Arcoxia. // TCE: The Chemical Engineer;May2007, Issue 791, p5
The article reports that an advisory committee to the U.S. Food and Drug Administration (FDA) has recommended that Merck's cyclooxygenase-2 inhibitor, Etoricoxib, should not be approved. The committee pointed out that the risks associated with the drug, commonly known as Arcoxia, outweigh its...
- Out of sight. McLaughlin, Neil // Modern Healthcare;10/18/2004, Vol. 34 Issue 42, p26
Focuses on the problems facing the pharmaceutical industry in the U.S. Recall of Vioxx cyclooxygenase 2 inhibitor by Merck & Co.; Flu vaccine debacle; Emergence of reports on price gouging.
- A Painful Mistake. Gorman, Christine; Kher, Unmesh // Time;10/11/2004, Vol. 164 Issue 15, p48
This article discusses the impact of pharmaceutical giant, Merck, pulling its arthritis drug, Vioxx, off the market because of its health risks. A pharmaceutical company can rise and fall on the strength of a handful of blockbuster drugs, Vioxx was a giant. Unveiled with great fanfare by Merck...
- Merck s Loss Could Turn Out to be Pfizer's Gain. // Chemical Market Reporter;10/11/2004, Vol. 266 Issue 12, p12
Reports that Merck & Co.'s recall of the drug Vioxx (rofecoxib), a Cox-2 inhibitor, could actually boost the revenue at Pfizer Inc.. Confidence that patients will not abandon Cox-2 inhibitor drugs completely; Pfizer's competing Cox-2 inhibitors, Celebrex and Bextra; Patient safety concerns
- Pharma Prophet. Herper, Matthew // Forbes Global;2/7/2005, Vol. 8 Issue 2, p60
Focuses on pharmacologist Garret FitzGerald and his views on Cox-2-inhibitor drugs from Merck and Pfizer. Forecast on the market performance of the drug; Drug companies affiliated with Fitzgerald; Side effects of the drugs.
- In the face of CRISIS. Arnold, Matthew // Medical Marketing & Media;Feb2005, Vol. 40 Issue 2, p36
The article reports that the crisis over the safety of COX-2 inhibitors is almost certainly the most severe to hit the pharmaceutical industry in decades. At stake are the reputations not only of Merck & Co. Inc. and Pfizer Inc., whose corporate brands recently seemed armor plated, but of Big...
- Vioxx withdrawal spurs rivals into action. McGuire, Stephen // Medical Marketing & Media;Nov2004, Vol. 39 Issue 11, p12
This article reports that in the wake of Merck & Co. Inc.'s decision to withdraw Vioxx because of unfavorable clinical trials data, Pfizer and Boehringer Ingelheim/ Abbot Laboratories' stepped up efforts to promote their respective rival COX- 2 inhibitors, Celebrex and Mobic. Merck had pulled...